BioCentury | Feb 28, 2018
Distillery Therapeutics

Neurology

...non-human primate models of AD. TARGET/MARKER/PATHWAY: Vimentin (VIM) LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
BioCentury | May 4, 2017
Translation in Brief

Tethered hope

...While the approach could apply to virtually any viral infection, researchers from Scripps and spinout Zebra Biologics Inc....
BioCentury | Apr 25, 2017
Distillery Techniques

Drug platforms

...virus-host receptor interactions without affecting normal receptor activity LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
...Richard A. Lerner, The Scripps Research Institute, La Jolla, Calif. email: rlerner@scripps.edu Michael Leviten The Scripps Research Institute Zebra Biologics Inc. Intercellular...
BioCentury | Mar 24, 2017
Strategy

Connecting in Kyoto

...companies including Ionis Pharmaceuticals Inc. , Eli Lilly and Co. , Rigel Pharmaceuticals Inc. and Zebra Biologics Inc....
...Bagsvaerd, Denmark Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Fransisco, Calif. University of Tokyo, Tokyo, Japan Zebra Biologics Inc....
BioCentury | Jan 12, 2017
Company News

Zebra Biologics, AbbVie deal

...2014 ). Zebra Biologics Inc. , Concord, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Inflammation, Antibodies Alex Himes AbbVie Inc. Zebra Biologics Inc....
BioCentury | Oct 29, 2015
Distillery Therapeutics

Therapeutics: Thrombopoietin receptor (CD110; Mpl)

...Turncoat", page 12) TARGET/MARKER/PATHWAY: Thrombopoietin receptor (CD110; Mpl) LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
BioCentury | Oct 29, 2015
Translation in Brief

Tumor turncoat

...by using an agonist antibody that turns acute myelogenous leukemia (AML) cells into NK cells. Zebra Biologics Inc....
BioCentury | Mar 3, 2014
Emerging Company Profile

Zebra Biologics: Antibody express

...Institutions Mentioned The Scripps Research Institute , La Jolla, Calif. Zebra Biologics Inc. , Boston, Mass. Sidebars Zebra Biologics Inc....
BioCentury | Jan 20, 2014
Company News

Zebra Biologics, Scripps Research Institute deal

...The institute granted newco Zebra Biologics exclusive, worldwide rights to IP covering a platform to generate and...
...an initial insider seed financing. The newco expects the funds to support activities through 2014. Zebra Biologics Inc....
BioCentury | Oct 14, 2013
Financial News

Zebra Biologics completes venture financing

Zebra Biologics Inc. , Boston, Mass. Business: Antibodies Date completed: 10/10/13 Type: Venture financing Raised: Not disclosed Investors: OPKO Health Inc.; company founders WIR Staff...
Items per page:
1 - 10 of 10
BioCentury | Feb 28, 2018
Distillery Therapeutics

Neurology

...non-human primate models of AD. TARGET/MARKER/PATHWAY: Vimentin (VIM) LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
BioCentury | May 4, 2017
Translation in Brief

Tethered hope

...While the approach could apply to virtually any viral infection, researchers from Scripps and spinout Zebra Biologics Inc....
BioCentury | Apr 25, 2017
Distillery Techniques

Drug platforms

...virus-host receptor interactions without affecting normal receptor activity LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
...Richard A. Lerner, The Scripps Research Institute, La Jolla, Calif. email: rlerner@scripps.edu Michael Leviten The Scripps Research Institute Zebra Biologics Inc. Intercellular...
BioCentury | Mar 24, 2017
Strategy

Connecting in Kyoto

...companies including Ionis Pharmaceuticals Inc. , Eli Lilly and Co. , Rigel Pharmaceuticals Inc. and Zebra Biologics Inc....
...Bagsvaerd, Denmark Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Fransisco, Calif. University of Tokyo, Tokyo, Japan Zebra Biologics Inc....
BioCentury | Jan 12, 2017
Company News

Zebra Biologics, AbbVie deal

...2014 ). Zebra Biologics Inc. , Concord, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Inflammation, Antibodies Alex Himes AbbVie Inc. Zebra Biologics Inc....
BioCentury | Oct 29, 2015
Distillery Therapeutics

Therapeutics: Thrombopoietin receptor (CD110; Mpl)

...Turncoat", page 12) TARGET/MARKER/PATHWAY: Thrombopoietin receptor (CD110; Mpl) LICENSING STATUS: Patent application filed; licensed to Zebra Biologics Inc....
BioCentury | Oct 29, 2015
Translation in Brief

Tumor turncoat

...by using an agonist antibody that turns acute myelogenous leukemia (AML) cells into NK cells. Zebra Biologics Inc....
BioCentury | Mar 3, 2014
Emerging Company Profile

Zebra Biologics: Antibody express

...Institutions Mentioned The Scripps Research Institute , La Jolla, Calif. Zebra Biologics Inc. , Boston, Mass. Sidebars Zebra Biologics Inc....
BioCentury | Jan 20, 2014
Company News

Zebra Biologics, Scripps Research Institute deal

...The institute granted newco Zebra Biologics exclusive, worldwide rights to IP covering a platform to generate and...
...an initial insider seed financing. The newco expects the funds to support activities through 2014. Zebra Biologics Inc....
BioCentury | Oct 14, 2013
Financial News

Zebra Biologics completes venture financing

Zebra Biologics Inc. , Boston, Mass. Business: Antibodies Date completed: 10/10/13 Type: Venture financing Raised: Not disclosed Investors: OPKO Health Inc.; company founders WIR Staff...
Items per page:
1 - 10 of 10